False-positive F-18 FDG uptake in PET/CT studies in pediatric patients with abdominal Burkitt's lymphoma
Authors:
- Walid OmarWOWalid Omar
- Iman SidhomISIman Sidhom
- Manal ZamzamMZManal Zamzam
- Iman ZakyIZIman Zaky
- Magdy HafezMHMagdy Hafez
- Hussein M. Abdel-DayemHAHussein M. Abdel-Dayem
- 1 March 2010
- journal article
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 31 (3) , 232-238
Abstract
In pediatric patients with abdominal Burkitt's lymphoma, the involvement of the gastrointestinal tract and abdominal lymph nodes are the main presenting feature of the disease. Chemotherapy is the main treatment modality and could be preceded by surgical excision of the abdominal masses. To achieve cure or long-term disease-free survival a balance has to be struck between aggressive chemotherapy and the probability of tumor necrosis secondary to treatment complicated by acute infections, perforation or intestinal bleeding. F-18 fluorodeoxyglucose-positron emission tomography/computed tomography (F-18 FDG-PET/CT) has been recommended over conventional imaging modalities for the follow-up of these patients and for monitoring treatment response. As the incidences of postchemotherapy complications are high, the positive predictive value of PET/CT studies in these patients is very low and the false-positive rate is high from acute infections and tumor necrosis. Accordingly, histopathological confirmation of positive lesions on F-18 FDG-PET/CT studies is essential. This is especially important as post-therapy complications might present with nonspecific and nonurgent symptoms. At the same time initiating a second course of salvage chemotherapy is risky. Retrospectively reviewed F-18 FDG-PET/CT studies for 28 pediatric patients with abdominal Burkitt's lymphoma and diffuse large B-cell lymphoma after their treatment with chemotherapy or surgery. Four positive studies were found. All had pathological verification and were because of acute inflammation and tumor necrosis and there was no evidence of viable tumor cells. One patient had multiple recurrent lesions in the abdomen after the initial surgical excision and before starting chemotherapy. The incidence of acute complications in this series is 10.7%. This study confirms the high incidence of tumor necrosis and inflammation after chemotherapy for the abdominal Burkitt's lymphoma and consequently, the incidence of true-positive F-18 FDG studies is low. This necessitates the need for histopathological confirmation of positive studies.Keywords
This publication has 19 references indexed in Scilit:
- 18 F-FDG PET in Pediatric Lymphomas: A Comparison with Conventional ImagingCancer Biotherapy and Radiopharmaceuticals, 2008
- Revised Response Criteria for Malignant LymphomaJournal of Clinical Oncology, 2007
- Gastrointestinal: Burkitt's lymphomaJournal of Gastroenterology and Hepatology, 2005
- Enteropathy-Type Intestinal T-Cell Lymphoma: Clinical Features and Treatment of 31 Patients in a Single CenterJournal of Clinical Oncology, 2000
- New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project.Journal of Clinical Oncology, 1998
- A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group [see comments]Blood, 1994
- Non-Hodgkin’s Lymphoma: Biologic Classification and Implication for TherapyPediatric Clinics of North America, 1991
- Extralymphatic involvement in diffuse non-Hodgkin's lymphoma.Journal of Clinical Oncology, 1983
- Gastrointestinal involvement in non-Hodgkin's lymphomaCancer, 1980
- Diffuse histiocytic lymphoma involving the gastrointestinal tractCancer, 1978